HLA-A*02:01/NY-ESO-1 TCR-T cell therapy (Pregene)

HLA-A*02:01/NY-ESO-1 TCR-T细胞疗法（普瑞金）

Report date: 2022/12/21 13:17:46

Base Information

Drug NameHLA-A*02:01/NY-ESO-1 TCR-T cell therapy (Pregene)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1
Therapy Area/IndicationsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Pregene Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen Pregene Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A